Table 4. Model details including chemotherapeutic agents, route of administration, median cumulative dose, and upper and lower quartiles (data set 1a).

Animal	Type	Chemotherapeutic agent	Route of administration	Median	Q1	Q3
Mouse	Hydroxamate histone deacetylase inhibitors	JNJ-26481585	Subcutaneous	32.5	23.75	41.25
	Other	Salinomycin	Intraperitoneal	140	140	140
	Platinum compounds	Cisplatin	Hindpaw	0.004	0.002	0.022
			Intraperitoneal	20.5	8.25	23
			Subcutaneous	0.15	0.15	0.15
		Oxaliplatin	Hindpaw	0.04	0.04	0.04
			Intraperitoneal	10	3	30
			Intravenous	23	13.5	31
			Subcutaneous	0.04	0.04	0.04
	Proteasome inhibitors	Bortezomib	Intraperitoneal	0.75	0.425	1.95
			Intravenous	6.4	6.4	6.4
			Subcutaneous	12	12	18
	Taxanes	Paclitaxel	Intraperitoneal	10	5	16
			Intravenous	190	165	230
			Subcutaneous	10	10	10
			Tail vein	75	75	75
	Vinca alkaloids	Vincristine	Intraperitoneal	0.7	0.2	3.9
Rat	Binding of growth factor inhibitors	Suramin	Intravenous	25	17.5	37.5
	Other	Methotrexate	Subcutaneous	3.75	3.75	3.75
	Platinum compounds	Carboplatin	Intraperitoneal	112.5	101.25	123.75
		Cisplatin	Intraperitoneal	10	5	15
			Intravenous	2	2	2
			Subcutaneous	8	8	8
		Oxaliplatin	Intraperitoneal	16	8	32
			Intravenous	2	2	8
	Proteasome inhibitors	Bortezomib	Intraperitoneal	0.7	0.6	1
			Intravenous	4.8	4.2	4.8
	Taxanes	Docetaxel	Intravenous	25	17.5	32.5
			Tail vein	10	10	10
		Paclitaxel	Intraperitoneal	8	7.25	8.5
			Intravenous	24.5	9.75	33.25
			Tail vein	8	8	8
			Intrathecala	6	3.1	13
		Nanoparticle albumin-bound paclitaxel	Intravenous	26.8	25.4	28.2
	Vinca alkaloids	Vincristine	Intraperitoneal	0.95	0.5	1
			Intravenous	0.435	0.2125	0.75
			Subcutaneous	0.42	0.42	0.42
			Tail	0.625	0.5625	0.6875

^a Drug doses are shown in mg/kg, except intrathecal paclitaxel, shown in ng.